Predictors of depression in breast cancer patients treated with radiation: Role of prior chemotherapy and nuclear factor kappa B
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Depression is common during and after breast cancer treatment. However, the role of specific therapeutic modalities and related biologic mechanisms remains unclear. Radiation is an essential component of breast‐conserving therapy and may contribute to depression in patients with breast cancer through the activation of inflammatory pathways. METHODS: Depressive symptoms and inflammatory mediators, including nuclear factor kappa B (NF‐κB), were assessed at baseline (before radiation), during radiation, and 6 weeks after radiation in 64 women who had stage 0 through IIIA breast cancer. RESULTS: No significant increases in depressive symptoms occurred during or after radiation, although a number of patients exhibited moderate‐to‐severe depression throughout the study. Multivariate analyses of baseline factors predictive of depression revealed that educational status, perceived stress, prior chemotherapy, and peripheral blood NF‐κB DNA binding all were independent predictors of persistent depressive symptoms after radiation (all P < .05). Of these factors, only prior chemotherapy was associated with inflammatory mediators, including NF‐κB DNA binding, soluble tumor necrosis factor‐alpha receptor 2, and interleukin‐6, which, in univariate analyses predicted depressive symptoms after radiation (all P < .05). Chemotherapy‐treated patients also exhibited an over‐representation of gene transcripts regulated by NF‐κB. CONCLUSIONS: Radiation was not associated with increased depressive symptoms in the current study, but of disease and treatment‐related factors, prior chemotherapy predicted significant depression after radiation. Longitudinal studies are warranted to investigate the relationship among prior chemotherapy, inflammation, and persistent depression after breast cancer treatment. Cancer 2013;119:1951–1959. © 2013 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“breast cancer survivors tend to exhibit an inflammation-depression association comparable with other populations [78–80]”
From Moderators of inflammation-related depression: a prospective study of breast cancer survivors (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression as a predictor of disease progression and mortality in cancer patients: A Meta‐Analysis
Satin, J. R., Linden, W., & Phillips, M. J. (2009) · Cancer · doi:10.1002/cncr.24561 · Cited by 972 · cited 1×
“Depression also has been associated with increased breast cancer mortality,(7,8) and clinical trials of interventions that reduce depressive symptoms have reported increased survival in women with metastatic disease.(7,9) Many factors may contribute to depression, including age at diagnosis, tumor stage, surgery, and…”
BackgroundPace, T. W. W., Mletzko, T. C., Alagbe, O., Musselman, D. L., Nemeroff, C. B., Miller, A. H., & Heim, C. M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1630 · Cited by 810
Self-citationNuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior
Koo, J. W., Russo, S. J., Ferguson, D., Nestler, E. J., & Duman, R. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910658107 · Cited by 607
Giese-Davis, J., Collie, K., Rancourt, K. M. S., Neri, E., Kraemer, H. C., & Spiegel, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4455 · Cited by 458
Raison, C. L., Borisov, A. S., Majer, M., Drake, D. F., Pagnoni, G., Woolwine, B. J., Vogt, G. J., Massung, B., & Miller, A. H. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.010 · Cited by 367 · cited 1×
“Relevant to depression, NF-jB activation induces inflammatory cytokines, which can access the brain in humans and activates a central inflammatory response associated with altered metabolism of serotonin involved in depression.(35) Stress-induced NF-jB activation leads to depressive-like behavior in rodents and inhibi…”
BackgroundSelf-citationInflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer
Bower, J. E., Ganz, P. A., Tao, M. L., Hu, W., Belin, T. R., Sepah, S., Cole, S., & Aziz, N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2584 · Cited by 315
Monk, J. P., Phillips, G., Waite, R., Kuhn, J., Schaaf, L. J., Otterson, G. A., Guttridge, D., Rhoades, C., Shah, M., Criswell, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2838 · Cited by 179 · cited 3×
“Of note, chemotherapy has been associated with NF-jB activation both in breast cancer tissue and in peripheral blood.(16,23) To further explore clinical and inflammatory factors associated with depression in women receiving radiation, we conducted a longitudinal study before, during, and after a standardized course of…”
BackgroundKawase, E., Karasawa, K., Shimotsu, S., Izawa, H., Hirowatari, H., Saito, A. I., Ito, K., & Horikawa, N. (2012) · Breast Cancer · doi:10.1007/s12282-010-0220-y · Cited by 36 · cited 2×
“Because previous studies have demonstrated a relationship between baseline distress and depression, distress was assessed by using the perceived stress scale (PSS), which has been used in multiple populations, including breast cancer patients undergoing radiation.(2,28)”
BackgroundMethod
Research works printed but not linked: 31
- 10.1016/j.breast.2009.11.007 · DOI · Paper page
- 10.1016/j.ijrobp.2010.06.037 · DOI · Paper page
- 10.1016/j.radonc.2011.01.014 · DOI
- 10.1016/j.breast.2012.01.013 · DOI · Paper page
- 10.1007/s00520-012-1508-6 · DOI
- 10.1186/bcr1744 · DOI · Paper page
- 10.1016/S0140-6736(11)61629-2 · DOI · Paper page
- 10.1097/NCC.0b013e318202520a · DOI
- 10.1016/j.breast.2006.11.003 · DOI · Paper page
- 10.1136/bmj.38343.670868.D3 · DOI · Paper page
- 10.1200/JCO.2005.02.0081 · DOI · Paper page
- 10.1200/JCO.2007.10.7805 · DOI · Paper page
- 10.1016/j.ijrobp.2003.10.008 · DOI · Paper page
- 10.1016/S0360-3016(01)01657-1 · DOI · Paper page
- 10.1111/j.1600-065X.2012.01099.x · DOI · Paper page
- 10.1158/1541-7786.MCR-07-0339 · DOI
- 10.1016/j.bbi.2010.09.010 · DOI · Paper page
- 10.1007/s10549-006-9322-9 · doi:10.1007/s10549-006-9322-9
- International Commission on Radiation Units and Measurements (ICRU), 1993, ICRU Report No. 50: Prescribing, Recording and Reporting Photon Beam Therapy
- Nezu AM, 2000, Practitioner's guide to empirically based measures of depression
- 10.1016/S0165-0327(98)00039-1 · DOI
- 10.1007/s00520-009-0653-z · DOI
- 10.1186/1471-2407-12-251 · DOI
- 10.1093/bioinformatics/19.2.185 · DOI · Paper page
- 10.1093/bioinformatics/btg242 · DOI · Paper page
- 10.1038/nprot.2008.211 · DOI · Paper page
- 10.1186/1745-6150-6-15 · DOI · Paper page
- 10.1074/jbc.272.23.14914 · DOI · Paper page
- 10.1155/2011/875307 · DOI · Paper page
- 10.1111/j.1349-7006.2010.01685.x · DOI
- 10.1200/JCO.2011.36.1154 · DOI · Paper page
Cited by
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis
Jolly, M. K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00155 · Cited by 693
Felger, J. C., Li, Z., Haroon, E., Woolwine, B. J., Jung, M. Y., Hu, X., & Miller, A. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.168 · Cited by 620
Self-citationWhat does plasma CRP tell us about peripheral and central inflammation in depression?
Felger, J. C., Haroon, E., Patel, T. A., Goldsmith, D. R., Wommack, E. C., Woolwine, B. J., Le, N.-A., Feinberg, R., Tansey, M. G., & Miller, A. H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0096-3 · Cited by 448
Self-citationDepression in cancer: The many biobehavioral pathways driving tumor progression
Bortolato, B., Hyphantis, T. N., Valpione, S., Perini, G., Maes, M., Morris, G., Kubera, M., Köhler, C. A., Fernandes, B. S., Stubbs, B., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.004 · Cited by 375
Czarny, P., Wigner, P., Galecki, P., & Sliwinski, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.036 · Cited by 310
Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152
Self-citationDepression as a Risk Factor for Cancer: From Pathophysiological Advances to Treatment Implications
Currier, M. B., & Nemeroff, C. B. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061212-171507 · Cited by 126
Peiris-Pagès, M., Sotgia, F., & Lisanti, M. P. (2015) · Oncotarget · doi:10.18632/oncotarget.3828 · Cited by 115
Mehta, D., Raison, C. L., Woolwine, B. J., Haroon, E., Binder, E. B., Miller, A. H., & Felger, J. C. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.04.004 · Cited by 74
“…to non-responders were defined as having a P20% difference (1.2-fold change) corresponding to a <10% FDR (Cole et al., 2003; Miller et al., 2008; Torres et al., 2013) and cut-off of p 6 0.01 (Haider et al., 2008), and were therefore highly predictive based on both statistical significance (p…”
MethodSelf-citationHess, C. B., & Chen, A. M. (2014) · Psycho-Oncology · doi:10.1002/pon.3521 · Cited by 63
Moderators of inflammation-related depression: a prospective study of breast cancer survivors
Manigault, A. W., Ganz, P. A., Irwin, M. R., Cole, S. W., Kuhlman, K. R., & Bower, J. E. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01744-6 · Cited by 29
Circulating Cytokines as Predictors of Depression in Patients with Breast Cancer
Ho, H.-Y., Chin-Hung Chen, V., Tzang, B.-S., Hsieh, C.-C., Wang, W.-K., Weng, Y.-P., Hsu, Y.-T., Hsaio, H.-P., Weng, J.-C., & Chen, Y.-L. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.037 · Cited by 20
Metadata
- Authors
- Torres, M. A., Pace, T. W., Liu, T., Felger, J. C., Mister, D., Doho, G. H., Kohn, J. N., Barsevick, A. M., Long, Q., & Miller, A. H.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2013-03-19
- Volume
- 119
- Issue
- 11
- Pages
- 1951-1959
- ISSN
- 0008-543X
- 1097-0142
- Cited by
- 62
- References
- 8
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.